News & Events

Learn more about our accredited pharmacy that offers a wide range of patient-specific injectable and infusion medication nationwide 

Lucinda J. Van Anglen, B.S., Pharm.D., of Healix Infusion Therapy has been named a Fellow by the Infectious Diseases Society of America.

A multicenter, retrospective study evaluated adherence to therapy and POIC visits along with cost savings associated with therapy de-escalation in patients receiving self-administered OPAT through POICs.

The study was presented at the AAAAI 2022 Annual Meeting and was the first real-world patient-reported QOL survey in patients receiving IGSC 16.5%.

A study evaluated the distribution and resistance patterns of the Gram-negative pathogens (GNP) isolated from genitourinary patients treated in POICs over a 3-year period.

The coronavirus disease 2019 (COVID-19) pandemic dramatically affected the provision of healthcare in the U.S. with sharp declines in routine and elective healthcare services. A study evaluated how COVID-19 impacted the provision of OPAT in 14 POICs nationwide.

Stop by booth #746 to learn about how we help practices like yours provide a full continuum of care for your patients.

Healix is excited to once again present our collaborative Research at IgNS National Conference 2021.

An analysis of the initial impact of the COVID-19 pandemic on the rate of hospital patient referrals for outpatient antimicrobial therapy

Physician office infusion centers deliver lower cost and higher adherence — even during a pandemic.

In celebration of Pharmacy Week 2020, the entire team at Healix would like to sincerely thank all pharmacists, pharmacy technicians, and pharmacy personnel for their service and dedication to the pharmacy profession. 

Healix Infusion Therapy, LLC has demonstrated success in achieving hospital avoidance when providing outpatient antimicrobial therapy (OPAT) to patients with serious infections through physician offices.

Healix Infusion Therapy is pleased to announce that its collaborative research study regarding Immune Globulin Subcutaneous 16.5% (Cutaquig®) is now accessible in the AAAAI Annual Meeting Virtual Poster Hall.

The team at Healix would like to recognize and thank nurses across the nation for their dedication to the nursing profession and the time they sacrifice away from their loved ones to care for those in need.

Healix Infusion Therapy, LLC, announced today the publication of a collaborative study in theleading scientific journal, Open Forum Infectious Diseases.

The team at Healix would like to thank all the healthcare heroes who are on the front lines treating patients during this unprecedented time with the COVID-19 crisis.

Healix is proud to celebrate over 30 years of infusion excellence.

Healix Infusion Therapy is pleased to announce that it has been selected as a limited distribution network partner for Cutaquig by Octapharma AG. Cutaquig, Octapharma’s new subcutaneous immune globulin, launches this week.

Healix, the nation’s leader in providing physician office-based infusion services, will implement the Citus Health digital solution suite to streamline multi-office healthcare communications and automate documentation workflows to provide.

SUGAR LAND, TX (December 6, 2018) – Healix, the nation’s leader in providing physician office-based infusion services, announces a strategic partnership with WeInfuse, the first and only end-to-end workflow.

SUGAR LAND, TX (July 20, 2018) – Healix, the nation’s leader in physician office based infusion services, announced a strategic relationship with DoseMe, a precision dosing decision support platform specifically.

BOSTON and SUGAR LAND, Texas, December 18, 2017 – TA Associates, a leading global growth private equity firm, today announced that it has completed a strategic growth investment in Healix, a provider of outsourced.

SUGAR LAND, TX (July 28, 2017) – Healix Infusion Therapy, Inc. is proud to announce the relocation of its pharmacy operation to a new, state-of-the-art facility in Sugar Land, Texas. With more than 28.

SUGAR LAND, TX (July 28, 2017) – Healix® is Now a National Provider of Trogarzo™ (ibalizumab-uiyk). Trogarzo™ is a new humanized monoclonal antibody for the treatment of multidrug-resistant (MDR) HIV-1.

SUGAR LAND, TX (July 14, 2017) – Gram-positive osteomyelitis was successfully treated with telavancin, as published in an article in The International Journal of Antimicrobial Agents.

SUGAR LAND, TX (March 20, 2017) – Healix has been selected among an exclusive number of distributers to become a national provider of Cuvitru [Immune Globulin Subcutaneous (Human)] 20%. Immunologists who partner with Healix.

SUGAR LAND, TX (May 23, 2016) – Dalbavancin is a long-acting lipoglycopeptide, approved for the treatment of acute bacterial skin and skin structure infections caused by susceptible gram-positive bacteria. A retrospective study was.

SUGAR LAND, TX (January 25, 2016) – Pediatric outpatient antimicrobial therapy (OPAT) is increasing, however, data on management, safety, and clinical outcomes are limited. A two-year retrospective, observational study was conducted of 64 pediatric.

SAN DIEGO, CA (October 10, 2015) – Septicemia constitutes a major cause for 30-day hospital readmissions and is the most expensive condition treated in U.S. hospitals according to the Agency for Healthcare.

PHILADELPHIA, PA (October 10, 2014) – Outpatient antimicrobial therapy (OPAT) provided by a physician office infusion center revealed an overall low 30-day hospital admission rate of 6.8% compared to 26% previously reported. This collaborative, retrospective study.

PHILADELPHIA, PA (October 10, 2014) – Outpatient antimicrobial therapy (OPAT) in a physician office infusion center showed improved quality of care in contrast to a traditional home health care setting. A collaborative, retrospective study.

SAN FRANCISCO, CA (October 4, 2013) – A retrospective database review was conducted of patients aged 18 and older receiving ertapenem therapy for UTI between July 1, 2010, and December 31, 2013. Seventy-five patients with a UTI diagnosis.

SAN FRANCISCO, CA (October 4, 2013) – This study is a report of clinical and economic outcome data of a hospital-funded Indigent Healthcare Program conducted in 11 Infectious Disease (ID) Physician Office Infusion Centers (POICs).

SAN FRANCISCO, CA (October 4, 2013) – A multi-center retrospective review of 120 patients receiving intravenous antibiotics (IVAB) for complicated intra-abdominal infections (IAI) in a physician office infusion center (POIC) was conducted to determine the.

SAN FRANCISCO, CA (October 9, 2013) – A multi-center review of 100 patients receiving Vancomycin was conducted to determine the effectiveness of patient monitoring and the recognition of adverse events in an outpatient setting.

SUGAR LAND, TX – Multidrug-resistant osteomyelitis was successfully treated with telavancin, rifampin, and meropenem, as published in an article in The Annals of Pharmacotherapy. Primary author was Mary Beth Brinkman.

SAN DIEGO, CA (October 19, 2012) – A retrospective review of 1,352 patients treated at nine Infectious Disease POICs with intravenous antibiotics (IVAB) from January 1 to June 30, 2011, was conducted to assess the reduced risk level.

SAN DIEGO, CA (October 19, 2012) – A retrospective, multicenter review was conducted of eligible patients treated in the POIC from January 1- June 30, 2011, including 30-day follow-up to compare outcomes and costs in.

SAN DIEGO, CA (October 19, 2012) – A retrospective review was conducted of randomly selected records for patients treated in four Infectious Disease POICs from January 2010-December 2011, to compare patient management and outcomes in.

SAN DIEGO, CA (October 19, 2012) – A multi-center retrospective review of 11,616 patients receiving intravenous antimicrobials (IVAM) was conducted to determine utilization of IVAM in POICs and efficient device utilization. In the 65 participating.

SAN DIEGO, CA (October 19, 2012) – A retrospective pilot study was conducted of all patients, from January 2011 through April 2012, receiving OPAT under an indigent healthcare program (a hospital-funded program providing IV antibiotics through.

BOSTON, MA (October 21, 2011) – Patients receiving intravenous antibiotics in seven Infectious Disease Physician Office Infusion Centers (POICs) experienced a low rate of Clostridium difficile associated diarrhea (2.5 per 10,000 patient days). Of the 934.

BOSTON, MA (October 21, 2011) – A multi-center retrospective review of 203 patients treated with long term intravenous antibiotic therapy in physician office infusion centers (POICs) is effective with clinical success rates of 93% in bacteremia, 88%.

BOSTON, MA (October 21, 2011) – A 3-year trend analysis was conducted of patients initiated on intravenous antibiotics (IVAB) in an Infectious Disease Physician Office Infusion Center (POIC) during the years 2008 – 2010 for.

BOSTON, MA (October 21, 2011) – In a 16 month period, 47 patients were treated with telavancin in 15 physician office infusion centers (POICs) with indications for acute bacterial skin and skin structure infections (24), osteomyelitis (19), sepsis (3).

SUGAR LAND, TX (January 1, 2011) – Healix announced the official launch of the iPhone® compatible Healix App, a tool for on-the-go physicians to track formulary options with payer reimbursement data.